| Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation A Sabine, Y Agalarov, H Maby-El Hajjami, M Jaquet, R Hägerling, ... Developmental cell 22 (2), 430-445, 2012 | 443 | 2012 |
| NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis O Dormond, A Foletti, C Paroz, C Rüegg Nature medicine 7 (9), 1041-1047, 2001 | 389 | 2001 |
| PI3K and AKT: unfaithful partners in cancer S Faes, O Dormond International journal of molecular sciences 16 (9), 21138-21152, 2015 | 323 | 2015 |
| Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12 AK Singh, RK Arya, AK Trivedi, S Sanyal, R Baral, O Dormond, ... Cytokine & growth factor reviews 24 (1), 41-49, 2013 | 235 | 2013 |
| Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis C Rüegg, O Dormond, A Mariotti Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1654 (1), 51-67, 2004 | 209 | 2004 |
| Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase … M Bezzi, M Hasmim, G Bieler, O Dormond, C Rüegg Journal of Biological Chemistry 278 (44), 43603-43614, 2003 | 204 | 2003 |
| Prostaglandin E2 promotes integrin αVβ3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling O Dormond, M Bezzi, A Mariotti, C Ruegg Journal of Biological Chemistry 277 (48), 45838-45846, 2002 | 200 | 2002 |
| Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? C Rüegg, O Dormond, A Foletti Endothelium 9 (3), 151-160, 2002 | 198 | 2002 |
| DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport J Bernier-Latmani, C Cisarovsky, CS Demir, M Bruand, M Jaquet, ... The Journal of clinical investigation 125 (12), 4572-4586, 2015 | 194 | 2015 |
| Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells B Mastelic-Gavillet, B Navarro Rodrigo, L Décombaz, H Wang, ... Journal for immunotherapy of cancer 7, 1-16, 2019 | 186 | 2019 |
| The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells O Dormond, JC Madsen, DM Briscoe Journal of Biological Chemistry 282 (32), 23679-23686, 2007 | 162 | 2007 |
| Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma M Zoetemelk, M Rausch, DJ Colin, O Dormond, P Nowak-Sliwinska Scientific reports 9 (1), 7103, 2019 | 152 | 2019 |
| Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance AK Singh, RK Arya, S Maheshwari, A Singh, S Meena, P Pandey, ... International journal of cancer 136 (9), 1991-2000, 2015 | 144 | 2015 |
| Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer A Weiss, X Ding, JR Van Beijnum, I Wong, TJ Wong, RH Berndsen, ... Angiogenesis 18, 233-244, 2015 | 141 | 2015 |
| Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells G Scholz, C Jandus, L Zhang, C Grandclément, IC Lopez-Mejia, ... EBioMedicine 4, 50-61, 2016 | 123 | 2016 |
| Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease N Brakch, O Dormond, S Bekri, D Golshayan, M Correvon, L Mazzolai, ... European heart journal 31 (1), 67-76, 2010 | 120 | 2010 |
| Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo D Roulin, Y Cerantola, A Dormond-Meuwly, N Demartines, O Dormond Molecular cancer 9, 1-4, 2010 | 111 | 2010 |
| Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity S Faes, N Demartines, O Dormond Oxidative medicine and cellular longevity 2017 (1), 1726078, 2017 | 93 | 2017 |
| Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib D Roulin, L Waselle, A Dormond-Meuwly, M Dufour, N Demartines, ... Molecular cancer 10, 1-12, 2011 | 85 | 2011 |
| Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells D Datta, AG Contreras, A Basu, O Dormond, E Flynn, DM Briscoe, S Pal Cancer research 69 (23), 8902-8909, 2009 | 82 | 2009 |